+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2017-2025

  • Report

  • 140 Pages
  • April 2018
  • Region: Global
  • IndustryARC
  • ID: 4532524

PEGylation is the covalent coupling of non-toxic, hydrophilic polyethylene glycol (PEG) to dynamic pharmaceutical elements such as proteins, peptides, antibodies, colloids and others. PEGylation is routinely accomplished by incubation of a reactive derivative of PEG with the target molecule.

PEGylation raises strength and solubility of the drug and decreases immunogenicity by changing the electrostatic binding, confirmation, and hydrophobicity of the particle. The rise in adoption of PEGylation to treat various chronic diseases and the applications in PEGylation is the key factor that is driving the PEGylation market.

PEGylation is the process of suitable functionalization of the PEG polymer at one or both terminals. PEGs that are actuated at every end with the same responsive half are known as "homobifunctional", though if the useful gatherings present are distinctive, then the PEG derivative is referred as "heterofunctional." The chemically dynamic or activated derivatives of the PEG polymers are set up to attach the PEG to the desired molecule.

PEGylated proteins have wide applications and preferences over traditional treatment, as a result, the adoption is high. Failure of drug development and recall of products are the factors which will affect the PEGylated proteins market.

PEGylated proteins market is divided into four different geographic regions. North America and Europe are the major markets for PEGylated proteins. Countries in these regions are well developed and patients are very conscious about the diseases and available treatments. Increasing prevalence of chronic diseases and rise in health care spending are expected to drive the market in Asia-Pacific.

Sample companies profiled in this report are:
Merck Millipore (U.S.),
NOF Corporation (Japan),
Celares GmbH (Germany),
Biomatrik, Inc, (China),
Thermo Fisher Scientific, Inc. (U.S.)

Table of Contents

1. PEGylated Proteins Market Overview2. PEGylated Proteins Market Executive Summary
3. PEGylated Proteins Market Landscape
3.1 Market Share Analysis
3.2 Product Benchmarking
3.3 End User Profiling
3.4 Patent Analysis
3.5 Top 5 Financial Analysis

4. PEGylated Proteins Market Forces
4.1 Market Drivers
4.2 Market Restraints & Challenges
4.3 Opportunities
4.4 Porter’s Five Forces Analysis
4.4.1 Power of Suppliers
4.4.2 Power of Buyers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitution
4.4.5 Degree of Competition

5. PEGylated Proteins Market – Strategic Analysis
5.1 Value Chain Analysis
5.2 Pricing Analysis
5.3 Product/Market Life Cycle Analysis
5.4 Suppliers & Distributors

6. PEGylated Proteins Market - By Consumables
6.1 Introduction
6.2 PEGylation Kits
6.3 Reagents

7. PEGylated Proteins Market - By Services, Protein Type
7.1 Introduction
7.2 mAbs
7.3 Interferons

8. PEGylated Proteins Market - By Application
8.1 Introduction
8.2 Cancer Treatment
8.3 Chronic Kidney Diseases

9. PEGylated Proteins Market- By End-User
9.1 Introduction
9.2 Pharmaceutical
9.3 Biotechnology Companies

10. PEGylated Proteins Market- By Geography
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 U.K.
10.3.2 Germany
10.3.3 France
10.3.4 Italy
10.3.5 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia-Pacific
10.5 Rest of the World (RoW)
10.5.1 South America
10.5.2 Middle East
10.5.3 Africa

11. PEGylated Proteins Market Entropy
12. Company Profiles
12.1 Merck Millipore
12.2 Thermo Fisher Scientific Inc.
12.3 NOF American Corporation
12.4 Jenkem Technology
12.5 Creative Pegworks
12.6 Celares GmbH
12.7 Quanta Biodesign, Ltd
12.8 Biomatrik, Inc.
12.9 Iris Biotech GmbH
12.10 Laysan Bio, Inc.
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"